PARP inhibitor with or without an angiogenesis inhibitor for HRD advanced ovarian, fallopian-tube, or primary peritoneal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized Phase 2/3 trial comparing a PARP inhibitor alone versus a PARP inhibitor combined with the angiogenesis inhibitor bevacizumab in people with HRD high-grade serous or endometrioid ovarian, fallopian-tube, or primary peritoneal cancer. Eligible participants are adults with stage III–IV disease, ECOG 0–1, and no contraindications to chemotherapy or bevacizumab. The study includes surgical assessment (diagnostic laparoscopy or cytoreductive surgery) and regular follow-up to monitor tumor response, progression-free survival, and safety. Treatment tolerability and rates of disease control will be compared between the two groups.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18-≤75 years.
* Histologically confirmed diagnosis of serous or endometrioid high-grade ovarian cancer, fallopian-tube cancer or primary peritoneal cancer.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Possibility of performing diagnostic laparoscopy or cytoreductive surgery.
* Presence of homologous recombination deficiency (HRD).
* No contraindications to chemotherapy, or bevacizumab.
* Signed informed consent to participate in the study.

Exclusion Criteria:

* Presence of another active malignant invasive neoplasm.
* Pregnancy or lactation period.
* Disease progression during treatment.

Where it's running

• N.N. Alexandrov National Caner Centre
  Minsk, Lesnoy, Belarus Recruiting

Study contacts

• Study coordinator: Hanna Trukhan
• Email: annavladimir@rambler.ru
• Phone: 80291985715

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• Romiplostim N01 plus ATRA for persistent chemotherapy-induced low platelets after remission from gynecologic, breast, or lung cancer

  This trial tests whether adding ATRA to Romiplostim N01 helps people keep a safe platelet count after finishing chemotherapy for certain cancers.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07586826

• Aitua plus Nab-Paclitaxel and Carboplatin before surgery for advanced high-grade serous ovarian cancer

  This trial tests whether adding the PD-1/CTLA-4 bispecific antibody Aitua to standard neoadjuvant chemotherapy helps achieve complete tumor removal before interval debulking surgery in newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer patients who are not expected to be debulked to no visib

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07432594

• Giving TORL-1-23 with chemotherapy before initial surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer

  This study will test whether adding TORL-1-23 to standard paclitaxel and carboplatin before initial surgery helps women with advanced (FIGO III/IV) ovarian, fallopian tube, or primary peritoneal cancer whose tumors are CLDN6-positive.

  Recruiting at 7 sites Phase 1/2 TORL Biotherapeutics, LLC · Fullerton, California and 6 other locations · NCT07322094

• Evaluating a new treatment for recurrent ovarian cancer

  This study is testing a new treatment for women with recurrent ovarian cancer to see if it helps them live longer and feel better compared to standard care.

  Recruiting at 201 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 201 other locations · NCT06824467

• Ubamatamab alone and with other cancer drugs for platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

  This trial will test whether ubamatamab by itself or combined with bevacizumab, cemiplimab, fianlimab, or pegylated liposomal doxorubicin helps adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 56 sites Phase 2 Regeneron Pharmaceuticals · Birmingham, Alabama and 55 other locations · NCT06787612

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.